freepik__the-style-is-candid-image-photography-with-natural__36042

Drone-Enhanced Emergency Medical Services: Redefining Ground Zero in Medical Emergencies

Written By: Priya Bhaware, M.Pharm Pharmacology

Reviewed and Fact-Checked By: Vikas Londhe, M.Pharm Pharmacology

freepik__the-style-is-candid-image-photography-with-natural__36043
Source: Freepik.com

Discover how drones are transforming emergency medical services with faster response times, real-world success stories like Rwanda’s Zipline, and the science behind drone-assisted critical care delivery

Introduction: A Race against Time

Imagine a rural village nestled deep in the hills, 30 miles from the nearest hospital. A 45-year-old farmer collapses from a sudden cardiac arrest. His family called the local emergency helpline, but due to poor roads and distance, the ambulance would take over 45 minutes. His survival window is less than 10 minutes. But something extraordinary happens within 4 minutes: a drone appears in the sky, delivering an automated external defibrillator (AED) to the family. Trained via mobile video instructions, they use the AED, and the man’s heartbeat is revived.

This is not science fiction; it is the future of emergency medical care, powered by drones.

In emergencies, rapid access to life-saving medical supplies can mean the difference between life and death. Countless lives are lost each year during the crucial minutes immediately following a medical crisis. Every minute saved in delivering help can increase the chance of survival by up to 10%.

Drones are changing the landscape of emergency medical services (EMS) by offering a faster, more efficient, and cost-effective channel of delivering assistance in medical emergencies. A drone’s ability to be set out in a flash enables it to reach medical emergency ground zero quickly, facilitating rapid assessment, locating patients, and delivering essential medical supplies and equipment, often overtaking traditional response methods. This improved response time can significantly enhance patient outcomes and sometimes save the life of the patient, especially in remote or underserved areas.

Drone Enhanced Medical Emergency Services

Drone Emergency Medical Services (DEMS) use highly independent Beyond Visual Line of Sight (BVLOS) drones to speedily deliver vital medical supplies such as Automated External Defibrillators (AEDs), critical medications, and diagnostic equipment directly to medical emergency locations such as cardiac arrest, stroke, postpartum hemorrhage, anaphylaxis, or trauma, where even a few minutes’ delay can cost lives.

Traditional emergency services are while life-saving but face several limitations, like traffic delays in urban settings or poor road infrastructure in rural regions, slow ambulance dispatch times, and limited reach in remote or disaster-prone areas.

Unmanned Aerial Vehicles (UAVs), commonly known as drones, are emerging as vital tools in healthcare logistics. Capable of bypassing traffic and terrain-related barriers, they can access both densely populated urban centers and hard-to-reach rural locations. The need for faster and more efficient emergency responses, especially in underserved or isolated areas, highlights the expanding role of drones in enhancing emergency medical services (EMS).

Drones can be deployed within seconds to deliver critical medical equipment ahead of ambulance arrival, while also transmitting real-time aerial footage to enhance situational awareness and support informed decision-making. In large-scale disasters or mass casualty incidents, they play a crucial role in coordinating resources and minimizing exposure risks for emergency personnel

Clinical Trials and Pilot Studies: Evidence behind the Buzz

Karolinska Institute, Sweden: Out-of-hospital cardiac arrest (OHCA) trial

7378858_32115_11zon

One of the most influential studies in this field was published in the New England Journal of Medicine (NEJM) in December 2022, titled “Drone Delivery of an Automated External Defibrillator.” Conducted in Sweden, this interventional trial evaluated the effectiveness of drones delivering AEDs (Automated External Defibrillators) in out-of-hospital cardiac arrest (OHCA) scenarios. The study involved 18 actual cardiac arrest cases in which drones were dispatched in parallel with emergency medical services. In 64% of these cases, the drones arrived before ambulances, achieving a median time saving of 2 minutes and 15 seconds—a significant reduction considering that survival from cardiac arrest drops by 7–10% for every minute without defibrillation. In three instances, bystanders successfully retrieved and used the drone-delivered AEDs before EMS arrived, marking a critical advancement in community-assisted emergency care. Importantly, no safety incidents were reported, proving the operational feasibility of drone delivery in populated areas.

U.S. FAA and WakeMed Hospital (North Carolina)

In the United States, a notable pilot project by WakeMed Hospital in North Carolina, in collaboration with UPS Flight Forward and Matternet, focused on transporting laboratory samples via drones. Over 2,000 successful drone flights were completed, demonstrating a 30–40 minute reduction in turnaround time for diagnostic tests a crucial factor in speeding up emergency treatment decisions, especially in stroke, sepsis, or trauma cases.

Zipline’s Internal Data (Rwanda & Ghana)

family-traveling-together-through-woods

Internationally, perhaps the most impactful real-world data comes from Zipline, a drone logistics company operating in Rwanda and Ghana. Though not part of a randomized clinical trial, Zipline has released comprehensive operational metrics. The drones have completed over 1 million deliveries, primarily of blood products, vaccines, antivenoms, and emergency medications, often to hard-to-reach rural clinics. Their data show a 75% reduction in delivery time compared to traditional ground transportation. In Rwanda, these drones have been especially critical in delivering blood for postpartum hemorrhage a leading cause of maternal mortality helping save thousands of lives by eliminating fatal delays.

India—Medicine from the Sky Project

freepik__the-style-is-candid-image-photography-with-natural__36041

In India, the government-led initiative “Medicine from the Sky” launched in Telangana and Himalayan regions and also tested the use of drones in delivering vaccines and emergency medications to remote tribal areas. This pilot, supported by the World Economic Forum and private healthcare providers, proved that drones could reduce delivery time by 20–30 minutes per mission and operate effectively across difficult terrain. Healthcare workers reported high levels of trust in the technology, and the pilot was deemed a success in improving access to urgent care supplies.

Step By Step Process of Drone Delivery

1. Emergency call triggered: When an emergency call (911/112) is made, both the Drone-Enhanced Emergency Medical Services (DEMS) and traditional EMS are activated simultaneously, ensuring a swift and coordinated response for faster on-site assistance.

2. Drone dispatched immediately: Within seconds, a DEMS drone is launched, carrying essential life-saving medical supplies such as defibrillators, haemorrhage control kits, or Naloxan. Its dynamic payload system allows for efficient customization based on the specific emergency, ensuring the right tools reach the scene as quickly as possible.

3. Arrival within 2-3 minutes: The DEMS drone reaches the emergency scene within 2–3 minutes—far faster than conventional EMS vehicles. It delivers critical equipment directly to bystanders or citizen responders on-site, empowering them to take immediate, potentially life-saving action before professional help arrives.

4. Real-time guidance provided: Using live video feeds and two-way communication, dispatchers guide bystanders through the process of administering life-saving actions, such as CPR, defibrillation, or the application of anti-bleeding kits. This ensures intervention is effective before EMS teams arrive.

5. EMS arrival and follow-up: Traditional EMS teams usually arrive within 9–10 minutes; however, by that time, crucial life-saving measures have often already been initiated by bystanders, guided by dispatchers, and equipped by DEMS drones. This early intervention greatly increases the patient’s chances of survival

Challenges

Airspace regulations and FAA compliance

Limited payload capacity (3-5 kg)

Battery life and weather limitations

Need for real-time coordination with EMS

Conclusion: A Sky Route for Saving Lives

Drones are revolutionizing emergency medical services by enabling faster, more efficient delivery of critical aid. They significantly reduce response times, especially in remote or congested areas, and improve patient outcomes through early intervention. Drones are not replacing emergency medical services they are augmenting them, creating a hybrid model where technology bridges critical care gaps in time and location. From Rwanda’s blood drops to India’s tribal medicine delivery, drones have ascended from concept to clinical impact.

As infrastructure, regulations, and technology evolve, drone-enhanced EMS is poised to become the new norm in global emergency care delivering not just medicines, but hope and life.

References

Revolutionized Healthcare: Drone Based Medical Services for Remote Healthcare and Emergency Response, available from https://www.aerogo.live/post/revolutionized-healthcare-drone-based-medical-services-for-remote-healthcare-and-emergency-response#:~:text=Here’s%20how%20drones%20are%20transforming,and%20enhance%20emergency%20response%20capabilities.

Sanz-Martos S, Lopez-Franco MD, Álvarez-García C, Granero-Moya N, Lopez-Hens JM, Camara-Anguita S, Pancorbo-Hidalgo PL, Comino-Sanz IM. Drone applications for emergency and urgent care: a systematic review. Prehospital and disaster medicine. 2022 Aug;37(4):502-8. DOI: 10.1017/S1049023X22000887

Habibi S, Ivaki N, Barata J. A Systematic Literature Review of Unmanned Aerial Vehicles for Healthcare and Emergency Services. arXiv preprint arXiv:2504.08834. 2025 Apr 10. https://doi.org/10.48550/arXiv.2504.08834

Schaerbeek S, Svensson L, Claesson A. Use of a drone-delivered automated external defibrillator in an out-of-hospital cardiac arrest. New England Journal of Medicine. 2022 May 19; 386(20):1953-4. Doi:10.1056/NEJMc2200833

Aggarwal S, Gupta P, Mahajan N, Balaji S, Singh KJ, Bhargava B and Panda S (2023) Implementation of drone based delivery of medical supplies in North-East India: experiences, challenges and adopted strategies. Front. Public Health 11:1128886. Doi: 10.3389/fpubh.2023.1128886Sharma S, Sharma H. Drone a technological leap in health care delivery in distant and remote inaccessible areas: A narrative review. Saudi J Anaesth. 2024 Jan-Mar;18(1):95-99. Doi: 10.4103/sja.sja_506_23. Epub 2024 Jan 2. PMID: 38313723; PMCID: PMC10833029.

Amukele, Timothy, Using drones to deliver blood products in Rwanda, The Lancet Global Health, Volume 10, Issue 4, e463 – e464

Rwanda signs agreement with zipline to use drones for delivery of essential medical products https://www.minict.gov.rw/news-detail/rwanda-signs-agreement-with-zipline-to-use-drones-for-delivery-of-essential-medical-products

Hospital Uses FAA-Approved Drones for the First Time, he American Society of Mechanical Engineers.

Medicine from the Sky: Community Outcomes of Drone Deliveries in the Himalayan Region, World Economic Forum

 https://www3.weforum.org/docs/WEF_Medicine_from_the_Sky_2024.pdf

Step-by-step breakdown of DEMS, https://dems.se/

 

12428327_4963977

NEJM Commentary: FDA Says Updated Evidence-Based COVID-19 Vaccine Policy Represents the Scientific Gold Standard

Written by Rikesh Dhanraj Dighore (M.Pharm Pharmacology)

12428327_4963977
"The FDA's new Covid-19 philosophy represents a balance of regulatory flexibility and a commitment to gold-standard science (Source: Freepik.com)

On May 20, 2025, the U.S. Food and Drug Administration’s (FDA) Centre for Biologics Evaluation and Research (CBER) introduced a major change in COVID-19 vaccination policy, highlighting an evidence-based approach. This new strategy, published as a commentary in the New England Journal of Medicine, authored by FDA Commissioner Dr. Marty Makary and CBER Director Dr. Vinay Prasad, aims to adapt vaccine recommendations based on individual risk profiles and robust clinical data.

Key Changes in Vaccination Policy

The FDA’s revised guidelines prioritize COVID-19 booster vaccinations for individuals aged 65 and older, as well as those with underlying health conditions that increase the risk of severe illness, such as asthma, diabetes, obesity, cancer, several heart conditions, and pregnancy. For healthy individuals under 65, the FDA now requires vaccine manufacturers to provide data from randomized controlled trials demonstrating clear clinical benefits, such as reduced hospitalizations and deaths, before approval of booster doses.

The FDA’s New Direction in Vaccine Policy

In response to emerging data and waning public engagement, the FDA has established a staged COVID-19 vaccination guideline centered on risk stratification and scientific precision.

1. High-Risk Populations (Age 65+ or with comorbidities): These individuals will continue to be prioritized for vaccination. Immunogenicity data showing antibody response will be sufficient for regulatory approval in this group.

2. Low-Risk Populations (6 months to 64 years, no risk factors): For these individuals, further randomized controlled trials (RCTs) demonstrating clinical benefit (such as reduced symptomatic infection or hospitalization) will be required before broad licensure is granted.

3. Post-Marketing Trials: The FDA is encouraging manufacturers to conduct RCTs in healthy individuals aged 50–64, a group considered to be in “global equipoise.” These trials should have at least 6 months of follow-up and assess symptomatic COVID-19 as the primary endpoint, alongside secondary metrics like hospitalization and deaths.

4. Underlying Risk Factors: As outlined by the CDC, these include chronic diseases (e.g., diabetes, heart disease, and obesity), immunosuppression, and even mental health conditions such as depression. Over 100 million Americans fall under these high-risk categories and will remain eligible for vaccination under the new framework.

Rationale behind the Shift

This policy change reflects increasing evidence that repeated booster doses may offer limited additional protection for healthy individuals with prior infections or vaccinations. The FDA’s approach aligns with global trends, where booster recommendations are increasingly in focus on high-risk populations in Canada, Europe and Australia.

Key Opinion and Implications for Vaccine Manufacturers and Public Health

A new CBER director, Dr. Vinay Prasad, and FDA commissioner Dr. Martin A. Makary wrote in this commentary, “The FDA’s new Covid-19 philosophy represents a balance of regulatory flexibility and a commitment to gold-standard science.

Vaccine manufacturers, including Pfizer and Moderna, have expressed support for the FDA’s new evidence-based framework and are committed to conducting the necessary clinical trials.

However, some public health experts express concern that the policy could limit vaccine access for those who still desire it, including parents and their children, and potentially undermine public confidence in the vaccination programs.

Dr. Paul Offit, a vaccine expert at Children’s Hospital of Philadelphia, asked a question: “Is the pharmacist going to determine if you’re in a high-risk group?” Further, he added, “The only thing that can come of this will make vaccines less insurable and less available.”

Conclusion

The FDA’s CBER is navigating COVID-19 vaccination policy toward a more targeted, data-driven approach, focusing on protecting those at highest risk. While this strategy may optimize resource allocation and address vaccine fatigue, it also presents challenges in ensuring equitable access and maintaining public trust in vaccination efforts.

References

Prasad V, Makary MA. An Evidence-Based Approach to Covid-19 Vaccination. New England Journal of Medicine. 2025 May 20. Doi: 10.1056/NEJMsb2506929

FDA tightens requirements for COVID vaccine, adding trials for healthy adults, Reuters, 21 May 2025, https://www.reuters.com/business/healthcare-pharmaceuticals/fda-sets-new-covid-booster-guidelines-requiring-trials-approvals-healthy-adults-2025-05-20/

What the New COVID-19 Vaccine Guidance Means for You, 21 May 2025, Time Magazine, https://time.com/7287451/fda-new-covid-19-vaccine-guidance/

FDA’s New Risk-Based Approach to COVID-19 Vaccines Aims to Ease ‘Public Distrust’: Makary, Prasad, Biospace, 20 May 2025, https://www.biospace.com/fda/fdas-new-risk-based-approach-to-covid-19-vaccines-aims-to-ease-public-distrust-makary-prasad

FDA to limit covid shot approval to 65+, those with medical conditions, 20 May 2025, Washington post https://www.washingtonpost.com/health/2025/05/20/covid-vaccine-elderly-high-risk-fda/?utm_source=chatgpt.com

FDA says it will limit access to Covid-19 boosters for Americans under 65, 20 May 2025, the guardian https://www.theguardian.com/us-news/2025/may/20/fda-limits-covid-19-boosters?utm_source=chatgpt.com

The article is extensively reviewed and fact-checked by the editorial team of pharmacally.com

freepik__the-style-is-candid-image-photography-with-natural__78943

WHO 2025 Guidelines: Strategies to Prevent Adolescent Pregnancy in Low and Middle- Income Countries (LMICs)

freepik__the-style-is-candid-image-photography-with-natural__78943

Introduction

Adolescent pregnancy is still a big health problem around the world, especially in low and middle-income countries. Every year, millions of young girls become mothers, which can harm their health and make it harder for them to finish school or have a better future. To help fix this, the World Health Organization (WHO) has made new guidelines and recommendations to prevent early pregnancies and protect young girls from its adverse effects.

The Scale of the Problem

Every year, about 21 million girls between the ages of 15 and 19 in LMICs countries get pregnant, and about half of these pregnancies are not planned or intentional. In 2021, over 12 million girls aged 15 to 19 and nearly 500,000 girls aged 10 to 14 gave birth. These numbers show that we need to take action, especially in places like sub-Saharan Africa and Latin America, where adolescent pregnancy is most common.

Health and Social Consequences

Adolescent girls who become mothers have a higher chance of facing serious health problems during pregnancy and childbirth. Their babies are also at greater risk of infant mortality. Early pregnancy can also cause big problems in their lives many girls have to leave school, find it harder to get a good job, and may stay poor. Child marriage makes things worse, as young brides often have many pregnancies, feel stressed or sad, and have less control over their own lives.

Underlying Causes of Adolescent Pregnancy

There are many reasons why adolescent pregnancy is common in LMICs’ countries:

Child Marriage: In some cultures, girls are expected to marry before they turn 18, which often lead to early pregnancy.

Lack of Education: Girls who don’t go to school or drop out early are more likely to become pregnant. Education helps them to acquire knowledge of self protection and important skills that can delay marriage and pregnancy.

Poor Access to Health Services: Many adolescents can’t get proper sexual and reproductive information, birth control, or information about their body and their rights.

Gender Inequality: In some places, girls don’t have a community among themselves, which reduces their ability to make informed decisions about sex and contraception.  

Sexual Abuse: Some adolescent pregnancies happen because of forced sex or abuse, which puts girls in even more danger.”

Progress and Remaining Challenges

There has been some good progress in the last 20 years. The number of adolescent births around the world was declined by 34% from 2000 to 2021, and child marriage dropped by 24% between 2010 and 2020. This happened because of better education about sex, community support, and helpful government policies.

But not everyone is seeing these improvements. Girls who live in rural areas, have little education, or come from low-income families are still at risk. Weak health systems and missing policies are still making it hard for many girls to get the help they need.

WHO’s Updated Recommendations

The World Health Organization (WHO) knows there has been progress and many challenges. So, in its new 2025 guideline, WHO suggests two main ways to help

1. Recommendations to Reduce Child Marriage and help married girls

Rec. 1: Teaching girls’ important skills, building their knowledge, assets and build support from society.

Rec 2: WHO recommended the programmes which aims to reduce child marriages and supporting married girls by involving parents and guardians and especially boys and men and subsequently involving broader community to create and sustain gender equitable environment in society.

Rec 3: WHO recommended giving conditional rewards for girls who at the highest risk of child marriage to increase or extend their school attainment and delay marriage as a part of broad strategy under social protection interventions.

Rec 4: WHO recommended removing gender related obstacle and making sure girls can go to school for at least 12 years and get quality education.

Rec 5: WHO recommended that the adolescent girls should be economically empowered by increasing their financial literacy, knowing the importance of savings and access to employment skills that can expand their alternative options to marriage before turning 18.

Rec 6: WHO recommended creating laws and policies that restrict marriages in general before the age of 18. These laws and policies should be uniform with the standards of human rights.

2. Better Access to Birth Control (Contraceptives)
To improve adolescents’ use of contraceptives, WHO suggests:

Rec 1: WHO recommends programs that help adolescents challenge harmful gender norms and build confidence so they can make informed choices about using contraception.

Rec 2: WHO recommends programs that change unfair gender and social rules to help adolescents make their own choices about contraception and to make it easier for them to get and keep using it.

Rec 3: People of reproductive age should have the option to give themselves injectable contraception as another way to access it.

Oral contraceptive pills (OCPs) should be available without a prescription for people who use them.

Emergency contraceptive pills should be available without a prescription for anyone who wants to use them.

Women should be able to get up to a one-year supply of contraceptive pills based on their needs and preferences. Programs should make sure pills are easy to get while also managing supplies well. The system should be flexible so women can get the amount they need when they need it.

Rec 4: WHO recommends taking steps to lower the cost of contraception so that adolescents can afford to start using it and keep using it.

Rec 5: WHO recommends using accurate and safe digital health tools for adolescents as part of sexual and reproductive health programs

Good Practice Statement

Apart from recommendations, WHO has given some good practice statements to prevent child marriages and adolescent pregnancies and better access to contraceptives.

  1. Important leaders like those in politics, government, religion, and local traditions should be encouraged to help stop child marriage and support girls’ rights. These people are even encouraging access to, use of, and continued use of contraception among adolescents.
  2. Efforts to support women and girls should also include the specific needs and rights of girls who are married or living with a partner, whether formally or informally.
  3. Adolescents, including those who are married or living with a partner, should be actively involved in planning, designing, and reviewing programs that support their needs and rights.
  4. Programs to improve the quality of health services should be put in place to help adolescents access, start using, and continue using contraception.
  5. Laws and policies about age, marriage, and consent should be clear and supportive so that adolescents can access sexual and reproductive health services and contraceptives more easily and keep using them.
  6. Adolescents should be actively involved in planning, carrying out, and reviewing programs that support their contraceptive needs and rights.

Global and Local Implementation

The new WHO guidelines highlight that every country and community is different, so plans should be made to fit local needs. WHO is working with other groups like United Nations Population Fund (UNFPA), Girls Not Brides, and Family Planning 2030 to help governments in

Running awareness campaigns

Training local workers and leaders

Giving expert help and advice

Sharing successful ideas and strategies that have worked in other places

Conclusion

Preventing adolescent pregnancy is not only a health priority but also a matter of equity and human rights. Investing in adolescent girls’ education, empowerment, and access to quality health services is essential for building healthier and more resilient community. When girls get a good education, learn about their bodies, and feel confident, they can make better choices for their lives. WHO’s guidelines give countries a clear plan to help every adolescent girl live a healthier, safer, and better life.

References:

WHO releases new guideline to prevent adolescent pregnancies and improve girls’ health, 23 April 2025, World Health Organization

WHO guideline on preventing early pregnancy and poor reproductive outcomes among adolescents in low- and middle-income countries. Geneva: World Health Organization; 2025. Licence: CC BY-NC-SA 3.0 IGO.

Adolescent pregnancy, 10 April 2024, World Health Organization

Emergency contraception, 09 November 2021, World Health Organization

Crooks R, Bedwell C, Lavender T. Adolescent experiences of pregnancy in low-and middle-income countries: a meta-synthesis of qualitative studies. BMC Pregnancy Childbirth. 2022 Sep 12; 22(1):702. Doi: 10.1186/s12884-022-05022-1. PMID: 36096763; PMCID: PMC9469636.

Sabet, Farnaz et al., The forgotten girls: the state of evidence for health interventions for pregnant adolescents and their newborns in low-income and middle-income countries, The Lancet, Volume 402, Issue 10412, 1580 – 1596

Navideh Noori, Joshua L Proctor, Yvette Efevbera, Assaf P Oron – The Effect of Adolescent Pregnancy on Child Mortality in 46 Low- and Middle-Income Countries: BMJ Global Health 2022;7:e007681.

avian influenza

From Poultry to People: The Rising Risk of Avian Influenza (Bird Flu)

Written By Pragati Ekamalli B.Pharm

Reviewed and Fact Checked by Vikas Londhe M.Pharm (Pharmacology)

avian influenza

Introduction

Bird flu, also known as avian influenza, is a sickness caused by Type A viruses. The first known case of a serious form of bird flu was reported in 1959, and in 1996, a specific strain called H5N1 was found in China. These viruses can infect farm animals like chickens and turkeys and can spread among wild aquatic birds like ducks and geese around the world. Some bird flu viruses can also affect other animals. Normally, humans do not get bird flu, but there have been rare cases where people became infected. This can happen when someone has close contact with sick birds or animals, especially if they touch their face after touching an infected animal or object. The virus can be found in the body fluids of infected animals.

History of avian influenza

In 1878, a vet in northern Italy saw many chickens dying. People didn’t understand viruses well then, so they named the sickness “fowl plague.” At first, it was mixed up with “fowl cholera,” which is caused by bacteria.

By 1901, scientists found out that “fowl plague” were caused by a virus. They figured this out because it could go through a filter, showing it was much smaller than bacteria. Later, technology showed that the virus was a type of H1N1 that affects birds.

In April 1981, at a meeting in First International Symposium on Avian Influenza  at Maryland, researchers decided to stop using the name fowl plague and called it highly pathogenic avian influenza (HPAI) instead.

Types of Avian Influenza

Low Pathogenic Avian Influenza (LPAI):   Low pathogenic avian influenza (LPAI) viruses typically cause mild or no symptoms in poultry and wild birds. However, in poultry, some LPAI strains can mutate into highly pathogenic forms.

Highly pathogenic avian influenza (HPAI): Highly harmful bird flu viruses, especially types A (H5) and A (H7), can make chickens very sick, often killing them within 48 hours. Most bird flu strains are less harmful, but some wild birds and ducks can carry the dangerous virus without showing signs of illness and spread it when they migrate. Some types can also kill wild birds, helping the virus spread around the world and putting both animals and people at risk.


Situation of Avian Influenza in USA

The first big outbreak of bird flu in the U.S. happened in Pennsylvania from 1983 to 1984, caused by the H5N2 strain, leading to the killing of over 17 million birds. In 2002-2003, a less severe H7N2 outbreak in Virginia led to more safety measures. The worst outbreak was in 2014-2015, when H5N2 and H5N8 strains affected the Midwest, resulting in the loss of over 50 million birds, especially in Iowa and Minnesota. Smaller outbreaks happened from 2016 to 2020, mostly affecting small farms and wild birds, highlighting the need for careful monitoring.

Currently, the U.S. is seeing cases of bird flu linked to the H5N1 strain, which has been spreading worldwide since 2021. This virus reached North America that same year, infecting many wild birds and farmed poultry in several states. Since 2022, many wild birds have tested positive for H5N1, and millions of farmed birds have been killed to stop the virus from spreading. Human cases have been rare, but there is still concern about possible transmission to people. A human case was confirmed in 2022 in Colorado involving a poultry worker who had mild symptoms and fully recovered.

In March 2024, H5N1 was found in U.S. dairy cows for the first time. The first infected herds were in Texas and Kansas, with more cases reported in over ten states. The virus was also found in raw milk and nasal swabs, leading to further investigations. This was the first time H5N1 affected large mammals in the U.S. In April 2024, a human case linked to dairy cattle was confirmed in Texas. The person, a dairy worker, had conjunctivitis and fully recovered.

While the overall risk to human health remains low, the continued spread of H5N1 among birds and now mammals represents a serious threat to the agricultural sector. The potential for viral mutations that could make human transmission more efficient is a key concern for health officials.

Current Human Avian Influenza Cases

As of April 2025, there have been several notable developments in human cases of avian influenza (bird flu), particularly involving the H5N1 subtype.

Mexico’s First Human Fatality: A 3-year-old girl from Coahuila, Mexico, tragically died from H5N1 infection, marking the country’s first confirmed human case. Investigations are ongoing to determine the source of infection, with tests on 38 close contacts returning negative results, indicating no immediate human-to-human transmission.

United States Occupational Exposures: In 2024, the U.S. reported 46 human H5N1 cases across six states, primarily among poultry and dairy workers. Most cases were mild, with no critical illnesses or fatalities. Notably, personal protective equipment (PPE) usage among these workers was found to be suboptimal.

Retrospective Worldwide fatality of H5N1

Indonesia: Indonesia has reported the highest number of human fatalities from avian influenza (H5N1) globally, with over 160 deaths since 2003. Most cases resulted from close contact with infected poultry.

Egypt: Egypt has had the highest number of H5N1 cases in the Middle East and Africa, with over 120 confirmed cases and more than 35 fatalities, primarily affecting rural areas with backyard poultry.

Vietnam: Vietnam has experienced 63 deaths from H5N1 since 2003. Despite aggressive control measures, sporadic outbreaks and fatalities have continued due to poultry exposure.

Cambodia: Cambodia has reported over 30 human cases of H5N1, with a high fatality rate, most of the infected individuals died, often due to delayed treatment in rural areas.

China: China has reported fewer human deaths compared to other countries, but still significant, with over 50 fatalities from H5N1 and other avian influenza strains like H7N9, which emerged in 2013.

Cumulative Global Cases: Since 2003, over 950 human H5N1 infections have been reported across 24 countries, with a case fatality rate of approximately 49%.

Public Health Response

Vaccine Development: In response to the growing threat, the U.S. Department of Health and Human Services has allocated $590 million to Moderna for the development of mRNA-based vaccines targeting multiple bird flu subtypes. ​

​Arcturus Therapeutics Holdings Inc. has received FDA clearance to initiate clinical trials for its H5N1 pandemic influenza vaccine candidate, ARCT-2304, also known as LUNAR-H5N1. This self-amplifying mRNA (sa-mRNA) vaccine utilizes Arcturus’ proprietary STARR® platform and LUNAR® delivery technology.

Surveillance Efforts: The Centers for Disease Control and Prevention (CDC) is actively monitoring the situation, utilizing flu surveillance systems to detect H5 bird flu activity in humans and working with states to monitor individuals with animal exposures, subsequently, in April 2025, the FDA granted Fast Track designation to ARCT-2304, aiming to expedite its development and review process.

Conclusion

Bird flu, especially the H5N1 type, has changed from a small problem in birds to a serious worry for both animals and people. More cases are being seen in wild birds, farm animals, and even cows. The virus is showing it can jump from one species to another. While there are not many human cases, the chance that it could change and spread more widely is a big concern. This shows we need to keep a close watch, respond quickly, and speed up vaccine development. As the situation develops, countries need to work together to reduce the risk of a future outbreak and keep people healthy and food supplies safe.

Introduction

Bird flu, also known as avian influenza, is a sickness caused by Type A viruses. The first known case of a serious form of bird flu was reported in 1959, and in 1996, a specific strain called H5N1 was found in China. These viruses can infect farm animals like chickens and turkeys and can spread among wild aquatic birds like ducks and geese around the world. Some bird flu viruses can also affect other animals. Normally, humans do not get bird flu, but there have been rare cases where people became infected. This can happen when someone has close contact with sick birds or animals, especially if they touch their face after touching an infected animal or object. The virus can be found in the body fluids of infected animals.

History of avian influenza

In 1878, a vet in northern Italy saw many chickens dying. People didn’t understand viruses well then, so they named the sickness “fowl plague.” At first, it was mixed up with “fowl cholera,” which is caused by bacteria.

By 1901, scientists found out that “fowl plague” were caused by a virus. They figured this out because it could go through a filter, showing it was much smaller than bacteria. Later, technology showed that the virus was a type of H1N1 that affects birds.

In April 1981, at a meeting in First International Symposium on Avian Influenza  at Maryland, researchers decided to stop using the name fowl plague and called it highly pathogenic avian influenza (HPAI) instead.

Types of Avian Influenza

Low Pathogenic Avian Influenza (LPAI):   Low pathogenic avian influenza (LPAI) viruses typically cause mild or no symptoms in poultry and wild birds. However, in poultry, some LPAI strains can mutate into highly pathogenic forms.

Highly pathogenic avian influenza (HPAI): Highly harmful bird flu viruses, especially types A (H5) and A (H7), can make chickens very sick, often killing them within 48 hours. Most bird flu strains are less harmful, but some wild birds and ducks can carry the dangerous virus without showing signs of illness and spread it when they migrate. Some types can also kill wild birds, helping the virus spread around the world and putting both animals and people at risk.

Situation of Avian Influenza in USA

The first big outbreak of bird flu in the U.S. happened in Pennsylvania from 1983 to 1984, caused by the H5N2 strain, leading to the killing of over 17 million birds. In 2002-2003, a less severe H7N2 outbreak in Virginia led to more safety measures. The worst outbreak was in 2014-2015, when H5N2 and H5N8 strains affected the Midwest, resulting in the loss of over 50 million birds, especially in Iowa and Minnesota. Smaller outbreaks happened from 2016 to 2020, mostly affecting small farms and wild birds, highlighting the need for careful monitoring.

Currently, the U.S. is seeing cases of bird flu linked to the H5N1 strain, which has been spreading worldwide since 2021. This virus reached North America that same year, infecting many wild birds and farmed poultry in several states. Since 2022, many wild birds have tested positive for H5N1, and millions of farmed birds have been killed to stop the virus from spreading. Human cases have been rare, but there is still concern about possible transmission to people. A human case was confirmed in 2022 in Colorado involving a poultry worker who had mild symptoms and fully recovered.

In March 2024, H5N1 was found in U.S. dairy cows for the first time. The first infected herds were in Texas and Kansas, with more cases reported in over ten states. The virus was also found in raw milk and nasal swabs, leading to further investigations. This was the first time H5N1 affected large mammals in the U.S. In April 2024, a human case linked to dairy cattle was confirmed in Texas. The person, a dairy worker, had conjunctivitis and fully recovered.

While the overall risk to human health remains low, the continued spread of H5N1 among birds and now mammals represents a serious threat to the agricultural sector. The potential for viral mutations that could make human transmission more efficient is a key concern for health officials.

Current Human Avian Influenza Cases

As of April 2025, there have been several notable developments in human cases of avian influenza (bird flu), particularly involving the H5N1 subtype.

Mexico’s First Human Fatality: A 3-year-old girl from Coahuila, Mexico, tragically died from H5N1 infection, marking the country’s first confirmed human case. Investigations are ongoing to determine the source of infection, with tests on 38 close contacts returning negative results, indicating no immediate human-to-human transmission.

United States Occupational Exposures: In 2024, the U.S. reported 46 human H5N1 cases across six states, primarily among poultry and dairy workers. Most cases were mild, with no critical illnesses or fatalities. Notably, personal protective equipment (PPE) usage among these workers was found to be suboptimal.

Retrospective Worldwide fatality of H5N1

Indonesia: Indonesia has reported the highest number of human fatalities from avian influenza (H5N1) globally, with over 160 deaths since 2003. Most cases resulted from close contact with infected poultry.

Egypt: Egypt has had the highest number of H5N1 cases in the Middle East and Africa, with over 120 confirmed cases and more than 35 fatalities, primarily affecting rural areas with backyard poultry.

Vietnam: Vietnam has experienced 63 deaths from H5N1 since 2003. Despite aggressive control measures, sporadic outbreaks and fatalities have continued due to poultry exposure.

Cambodia: Cambodia has reported over 30 human cases of H5N1, with a high fatality rate, most of the infected individuals died, often due to delayed treatment in rural areas.

China: China has reported fewer human deaths compared to other countries, but still significant, with over 50 fatalities from H5N1 and other avian influenza strains like H7N9, which emerged in 2013.

Cumulative Global Cases: Since 2003, over 950 human H5N1 infections have been reported across 24 countries, with a case fatality rate of approximately 49%.

Public Health Response

Vaccine Development: In response to the growing threat, the U.S. Department of Health and Human Services has allocated $590 million to Moderna for the development of mRNA-based vaccines targeting multiple bird flu subtypes. ​

​Arcturus Therapeutics Holdings Inc. has received FDA clearance to initiate clinical trials for its H5N1 pandemic influenza vaccine candidate, ARCT-2304, also known as LUNAR-H5N1. This self-amplifying mRNA (sa-mRNA) vaccine utilizes Arcturus’ proprietary STARR® platform and LUNAR® delivery technology.

Surveillance Efforts: The Centers for Disease Control and Prevention (CDC) is actively monitoring the situation, utilizing flu surveillance systems to detect H5 bird flu activity in humans and working with states to monitor individuals with animal exposures, subsequently, in April 2025, the FDA granted Fast Track designation to ARCT-2304, aiming to expedite its development and review process.

Conclusion

Bird flu, especially the H5N1 type, has changed from a small problem in birds to a serious worry for both animals and people. More cases are being seen in wild birds, farm animals, and even cows. The virus is showing it can jump from one species to another. While there are not many human cases, the chance that it could change and spread more widely is a big concern. This shows we need to keep a close watch, respond quickly, and speed up vaccine development. As the situation develops, countries need to work together to reduce the risk of a future outbreak and keep people healthy and food supplies safe.

References

1.Tripathi AK, Sendor AB, Sapra A. Avian Influenza. [Updated 2025 Feb 5]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan. Available from:https://www.ncbi.nlm.nih.gov/books/NBK553072/

2. Avian Influenza, World Organization for Animal Health, available from https://www.woah.org/en/disease/avian-influenza/

3. H5 Bird Flu: Current Situation, US centres for disease control and prevention, 11 April 2025, available from https://www.cdc.gov/bird-flu/situation-summary/index.html

 4. Confirmations of Highly Pathogenic Avian Influenza in Commercial and Backyard Flocks, Animal and Plant Health Inspection Service, U.S. Department Of Agriculture

5. Lycett SJ, Duchatel F, Digard P. A Brief History of Bird Flu. Philos Trans R Soc Lond B Biol Sci. 2019 Jun 24; 374(1775):20180257. Doi: 10.1098/rstb.2018.0257. PMID: 31056053; PMCID: PMC6553608.

 6. 2020-2024 Highlights in the History of Avian Influenza (Bird Flu) Timeline, US centres for disease control and prevention, 30 April 2024, available from https://www.cdc.gov/bird-flu/avian-timeline/2020s.html

7. What Are the Earliest Known Origins of Bird Flu? Available from https://www.history.com/articles/bird-flu-origins-humans-pandemic

8. Past Reported Global Human Cases with Highly Pathogenic Avian Influenza A (H5N1) (HPAI H5N1) by Country, 1997-2025, avian Influenza (Bird Flu), available from https://www.cdc.gov/bird-flu/php/avian-flu-summary/chart-epi-curve-ah5n1.html

9. Avian Influenza Weekly Update # 993: 11 April 2025, World Health Organization, available from https://www.who.int/westernpacific/publications/m/item/avian-influenza-weekly-update—993–11-april-2025

 10. Global Avian Influenza Viruses with Zoonotic Potential situation update, Animal Health, Food and Agriculture organization of United Nations, available from https://www.fao.org/animal-health/situation-updates/global-aiv-with-zoonotic-potential/en

11. Avian Influenza (H5N1) Vaccines: What’s the Status? American Society of Microbiology, 04 March 2025, available from https://asm.org/articles/2025/march/avian-influenza-h5n1-vaccines-what-status

 12. US awards Moderna $590 million for bird flu vaccine development, Reuters, January 18 2025, available from https://www.reuters.com/business/healthcare-pharmaceuticals/us-awards-moderna-590-million-bird-flu-vaccine-development-2025-01-17/

 13. Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for the STARR® mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1, Arcturus Therapeutics, 10 April 2025, available from https://ir.arcturusrx.com/node/13116/pdf

woman-researcher-looking-monitor-analysing-brain-scan-while-coworker-discussing-with-patient-background-about-side-effects_optimized_2000

From Paralysis to Vision Restoration: The Promise of Neuralink’s Brain Implants

By Team Pharmacally

Article Updated On: 07 May 2025

woman-researcher-looking-monitor-analysing-brain-scan-while-coworker-discussing-with-patient-background-about-side-effects_optimized_2000
Source: Freepik.Com

Neuralink, founded by Elon Musk, the neurotechnology company has taken great steps in getting FDA-certified brain implants, mainly in aiding individuals with paralysis and vision impairment.

Advancements in Assisting Paralysis

In January 2024, Neuralink implanted its N1 brain computer interface (BCI) chip into quadriplegic patient Noland Arbaugh. The implant allowed Arbaugh to control a computer cursor with his thoughts, marking a significant milestone in BCI technology. However, the device encountered some problems, such as the detachment of some electrodes, which affected its performance. Neuralink addressed these issues by refining their algorithms and surgical techniques. Then, another patient received a better implant that showed excellent stability and function. This patient was able to play video games and design 3D objects with computer-aided design software by August 2024.

Initiatives in Vision Restoration

In September 2024, the “Blindsight” implant from Neuralink received a so-called “breakthrough device” designation by the FDA. The implant is designed to restore vision for people who have both lost their eyes and their optic nerve. Optimistically, this may even benefit people born blind. According to the FDA, breakthrough devices are medical devices that provide a more effective treatment or diagnosis for a life-threatening or irreversibly debilitating condition. Although this acceptance speeds up the development process, it does not mean that the market will approve it right away. Neuralink has not yet set a date for human trials of the Blindsight implant. 

Regulatory Milestones and Future Directions

In May 2023, Neuralink received approval from the FDA to start conducting human clinical trials. The early tests have involved individuals with serious spinal cord injuries in order to determine the safety and effectiveness of the implants. The owner of the corporation, Elon Musk, has stated that he would want to increase the size of those participating in the experiments and that, by the end of 2025; devices will be implanted in 20 to 30 other people. These developments highlight Neuralink’s dedication to enhancing BCI technology for the improvement of life quality for those with neurological impairments.

In summary, Neuralink FDA-approved brain implants are reportedly showing much promise in early human trials, especially in restoring motor functions for paralyzed individuals. In addition to the ongoing vision restoration, the BCI technology is only expected to revolutionize the field to deal with other various neurological challenges.

Update on 07 May 2025 :

Neuralink Patient Edits YouTube Video Using Only His Mind

Brad Smith, a dad from Arizona who has ALS (amyotrophic lateral sclerosis), is the third person in the world and the first who can’t speak to get a brain chip from Neuralink. This chip lets him control a computer using just his thoughts, and he was able to make and narrate a YouTube video using only his brain.

The Neuralink chip was placed in the part of Brad Smith’s brain that controls movement. It lets him move a computer mouse by just thinking about certain actions, like moving his tongue or clenching his jaw. This worked better than trying to imagine moving his hands. The chip connects wirelessly to a MacBook, turning his thoughts into actions on the screen.

To help him speak again, Brad used artificial intelligence that was trained on recordings of his voice from before he got ALS. This AI recreated his voice, allowing him to narrate his video. It’s an important step forward in technology that helps people communicate.

Before getting the Neuralink chip, Brad used eye-tracking technology to communicate, but it only worked well in certain lighting. Now, with the brain chip, he can communicate more easily in different places, even outside. He can also do fun things like play video games with his kids, which has made his life better.

Brad’s story shows how brain chips like Neuralink can help people with serious physical challenges regain control and communicate again. His experience gives hope that this kind of technology can make life better for others with similar conditions in the future.

Video Source: Mr. Smith Gets a Neuralink Brain Implant and a Visit From Elon Musk – Neuralink (YouTube)

Disclaimer: “This video is shared from Neuralink’s official YouTube channel and used here for informational and educational purposes.”

References:

1. Neuralink implanted second trial patient with brain chip, Musk says, Reuters, 5 Aug 2024

2. Neuralink’s first brain chip implant developed a problem — but there was a workaround, CNN Business, 09 May 2024

3. Neuralink’s Brain Chip: How It Works and What It Means, Capitol Technology University, 09 Feb 2024

4. Waisberg, Ethan; Ong, Joshua1; Lee, Andrew G.2, 3,4,5,6,7,8,9. The potential to restore vision with Neuralink’s “Blindsight” neural interface technology. The Pan-American Journal of Ophthalmology 6(3):84, May 2024. | DOI: 10.4103/pajo.pajo_36_24

5. Musk’s Neuralink gets FDA’s breakthrough device tag for ‘Blindsight’ implant, Reuters, 18 Sept 2024

6. World First: Neuralink Patient Makes YouTube Video With Brain Implant, 06 May 2025, Sciencealert.com, available from https://www.sciencealert.com/world-first-neuralink-patient-makes-youtube-video-with-brain-implant